Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Launches An Operations Revamp
November 5, 2007
| A version of this story appeared in
Volume 85, Issue 45
Facing generic competition and a drop in sales of its diabetes drug Avandia, GlaxoSmithKline has launched a $3.1 billion operational cost reduction program that is expected to result in annual pretax savings of up to $1.5 billion by 2010. GSK says the initiative will improve efficiency in R&D, manufacturing, and sales. The company will pare its manufacturing sites and "streamline" R&D with an increased focus on biopharmaceuticals, oncology, vaccines, and neuroscience. GSK announced the plan as part of its third-quarter earnings. Sales of Avandia dropped 38% for the quarter to about $467 million.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X